Publications

G protein Inactivation as a Mechanism for Addiction Treatment.
(2025 Apr 4)
Biol Psychiatry
Neiswanger C, Ruiz MV, Kimball K, Lee JD, Land B, Berndt A, Chavkin C

G protein Inactivation as a Mechanism for Addiction Treatment.
(2024 Dec 17)
bioRxiv
Neiswanger C, Ruiz MV, Kimball K, Lee JD, Land B, Berndt A, Chavkin C

Ultra-fast genetically encoded sensor for precise real-time monitoring of physiological and pathophysiological peroxide dynamics.
(2024 Mar 25)
Res Sq
Berndt A, Lee J, Won W, Kimball K, Neiswanger C, Schattauer S, Wang Y, Yeboah F, Ruiz M, Evitts K, Rappleye M, Bremner S, Chun C, Smith N, Mack D, Young J, Lee CJ, Chavkin C

Structure-guided engineering of a fast genetically encoded sensor for real-time H(2)O(2) monitoring.
(2024 Feb 4)
bioRxiv
Lee JD, Won W, Kimball K, Wang Y, Yeboah F, Evitts KM, Neiswanger C, Schattauer S, Rappleye M, Bremner SB, Chun C, Smith N, Mack DL, Young JE, Lee CJ, Chavkin C, Berndt A

Optogenetic stimulation of dynorphinergic neurons within the dorsal raphe activate kappa opioid receptors in the ventral tegmental area and ablation of dorsal raphe prodynorphin or kappa receptors in dopamine neurons blocks stress potentiation of cocaine reward.
(2022 Mar)
Addict Neurosci 1():
Abraham AD, Casello SM, Land BB, Chavkin C

Ketamine Pharmacodynamics Entangled: Comment.
(2022 Dec 1)
Anesthesiology 137(6): 747-748
Bowdle TA, Sackett N, Strassman R, Murray TF, Jelacic S, Chavkin C

Stress decreases serotonin tone in the nucleus accumbens in male mice to promote aversion and potentiate cocaine preference via decreased stimulation of 5-HT(1B) receptors.
(2022 Mar)
Neuropsychopharmacology 47(4): 891-901
Fontaine HM, Silva PR, Neiswanger C, Tran R, Abraham AD, Land BB, Neumaier JF, Chavkin C

Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition.
(2021 Dec)
Neuropsychopharmacology 46(13): 2330-2339
Abraham AD, Casello SM, Schattauer SS, Wong BA, Mizuno GO, Mahe K, Tian L, Land BB, Chavkin C

Insidious Transmission of a Stress-Related Neuroadaptation.
(2020)
Front Behav Neurosci 14(): 564054
Steger JS, Land BB, Lemos JC, Chavkin C, Phillips PEM

Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action.
(2020 Nov)
Mol Pharmacol 98(5): 548-558
Reichard KL, Newton KA, Rivera ZMG, Sotero de Menezes PM, Schattauer SS, Land BB, Chavkin C

Will biased ligands be the opioids of the future?
(2020 Sep 1)
Pain 161(9): 1945-1948
Ballantyne JC, Chavkin C

Sequencing the serotonergic neuron translatome reveals a new role for Fkbp5 in stress.
(2021 Sep)
Mol Psychiatry 26(9): 4742-4753
Lesiak AJ, Coffey K, Cohen JH, Liang KJ, Chavkin C, Neumaier JF

Synergy of Distinct Dopamine Projection Populations in Behavioral Reinforcement.
(2020 Mar 4)
Neuron 105(5): 909-920.e5
Heymann G, Jo YS, Reichard KL, McFarland N, Chavkin C, Palmiter RD, Soden ME, Zweifel LS

Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation.
(2019 Nov 8)
J Biol Chem 294(45): 16884-16896
Schattauer SS, Bedini A, Summers F, Reilly-Treat A, Andrews MM, Land BB, Chavkin C

Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation.
(2019)
Front Pharmacol 10(): 88
Chavkin C, Cohen JH, Land BB

Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.
(2018 Sep 12)
J Neurosci 38(37): 8031-8043
Abraham AD, Schattauer SS, Reichard KL, Cohen JH, Fontaine HM, Song AJ, Johnson SD, Land BB, Chavkin C

Kappa-opioid antagonists as stress resilience medications for the treatment of alcohol use disorders.
(2018 Aug)
Neuropsychopharmacology 43(9): 1803-1804
Chavkin C

Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase.
(2017 Sep 29)
Nat Commun 8(1): 743
Schattauer SS, Land BB, Reichard KL, Abraham AD, Burgeno LM, Kuhar JR, Phillips PEM, Ong SE, Chavkin C

κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.
(2018 Jan)
Neuropsychopharmacology 43(2): 362-372
Abraham AD, Fontaine HM, Song AJ, Andrews MM, Baird MA, Kieffer BL, Land BB, Chavkin C

Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
(2017 Apr)
Cell Signal 32(): 59-65
Schattauer SS, Kuhar JR, Song A, Chavkin C